Ivosidenib

Ivosidenib
Clinical data
Routes of; administration	Oral
ATC code	None;
Legal status
Legal status	US: WARNING; Investigational;
Identifiers
	IUPAC name (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3- difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine2-carboxamide;
CAS Number	1448347-49-6;
PubChem CID	71657455;
ChemSpider	38772333;
UNII	Q2PCN8MAM6;
CompTox Dashboard (EPA)	DTXSID801027928 ;
Chemical and physical data
Formula	C28H22ClF3N6O3
Molar mass	582.97 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(=O)N([C@@H]1C(=O)N(C2=CC(=CN=C2)F)[C@@H](C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N;

Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The drug is being developed by Agios Pharmaceuticals and is in phase III clinical trials. The FDA awarded orphan drug status for acute myeloid leukemia and cholangiocarcinoma.^[2]^{[better source needed]}

Ivosidenib was approved by the FDA for acute myeloid leukemia (AML) with an IDH1 mutation and is presently in a phase III clinical trial for cholangiocarcinoma with an IDH1 mutation.^[3] Ivosidenib was the first anticancer therapy to approved for patients with a specific genetic variant (citation needed).

References

External links

Clinical trials registered for Ivosidenib

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[2] ttp://adisinsight.springer.com/drugs/800040155

[3] Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

[1]

[2]

[3]